-
公开(公告)号：US20240293444A1
公开(公告)日：2024-09-05
申请号：US18653713
申请日：2024-05-02
申请人： MedinCell S.A.
发明人： Christophe ROBERGE , Adolfo LÓPEZ-NORIEGA , Jean-Manuel CROS , Juliette SERINDOUX , Murielle OSTER , Fang LIU , Charlotte MOLINIER , Sylvestre GRIZOT , Tjasa VRLINIC , Feifei NG , Elise GUÉGAIN , Marie-Emérentienne CAGNON
IPC分类号： A61K31/765 , A61K9/00 , A61K31/445 , A61K31/4985 , A61K31/5415 , A61K31/675 , A61K31/7048 , A61K47/34
CPC分类号： A61K31/765 , A61K9/0024 , A61K31/445 , A61K31/4985 , A61K31/5415 , A61K31/675 , A61K31/7048 , A61K47/34
摘要： The present invention provides a pharmaceutical composition comprising:
a biodegradable multi-branched copolymer comprising at least three polyester arms attached to a central core which comprises a polyether, and wherein the multi-branched copolymer is substantially insoluble in aqueous solution, further comprising at least one pharmaceutically active ingredient.-
公开(公告)号：US20240269163A1
公开(公告)日：2024-08-15
申请号：US18567972
申请日：2022-06-08
发明人： Thomas A. KENT , Paul J. DERRY , Kenneth R. OLSON
IPC分类号： A61K31/765 , A61K9/00 , A61K31/385 , A61K47/69 , A61P43/00
CPC分类号： A61K31/765 , A61K9/0053 , A61K31/385 , A61K47/6921 , A61P43/00
摘要： A method of treating a Down syndrome (DS) subject with functional or at risk of decline of organ systems associated with accelerated aging due to over-production of H2S is disclosed. That method contemplates administering a pharmaceutical composition containing a H2S-reducing effective amount of hydrophilic polymer-substituted oxidized carbon nanoparticles (OCNPs) and an optional potentiating amount of lipoic acid or dihydrolipoic acid dissolved or dispersed in a physiologically acceptable diluent to the subject. The pharmaceutical composition can be administered parenterally as a liquid or per os as a solid or liquid.
-
公开(公告)号：US12036236B2
公开(公告)日：2024-07-16
申请号：US17507170
申请日：2021-10-21
IPC分类号： A61K31/765 , A61K31/155 , C08K5/31 , C08L69/00
CPC分类号： A61K31/765 , A61K31/155 , C08K5/31 , C08L69/00
摘要： Compositions and methods regarding antimicrobial guanidinium macromolecules with one or more targeting moieties for selectively targeting bacteria are provided. According to an embodiment, an antimicrobial macromolecule is provided that comprises a polymer backbone and one or more guanidinium moieties that extend from the polymer backbone. The antimicrobial macromolecule further comprises a targeting moiety that extends from the polymer backbone. The targeting moiety can comprise a substance favored for consumption by bacteria, such as a monosaccharide.
-
公开(公告)号：US20240000830A1
公开(公告)日：2024-01-04
申请号：US18330319
申请日：2023-06-06
申请人： onCour Pharma, Inc.
发明人： Daniel R. GETTS
IPC分类号： A61K31/78 , A61K9/00 , A61K39/00 , A61K39/39 , A61K31/01 , A61K31/74 , A61K31/765 , G01N33/68 , A61P35/00 , A61K9/14 , A61K31/00 , A61K9/16
CPC分类号： A61K31/78 , A61K9/0019 , A61K39/001 , A61K39/39 , A61K31/01 , A61K31/74 , A61K31/765 , G01N33/6893 , A61P35/00 , A61K9/14 , A61K39/0005 , A61K31/00 , A61K9/146 , A61K9/1647 , G01N2800/7095 , A61K2039/55555 , Y02A50/30
摘要： The current invention involves the administration of negatively charged particles, such as polystyrene, PLGA, or diamond particles, to subjects to ameliorate inflammatory immune responses. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same negatively charged particles.
-
公开(公告)号：US20230355660A1
公开(公告)日：2023-11-09
申请号：US18246122
申请日：2021-09-23
申请人： ABLEVIA BIOTECH GMBH
发明人： Oskar SMRZKA , Bettina WANKO
IPC分类号： A61K31/765 , A61K47/60 , A61P37/06
CPC分类号： A61K31/765 , A61K47/60 , A61P37/06
摘要： A compound for the sequestration of undesirable anti-polyethylene glycol (PEG) antibodies interfering with therapy by PEGylated active agents (such as PEGylated enzymes or antibodies) in a patient is provided. The compound includes an inert biopolymer scaffold and one or more PEG chains. Also provided are pharmaceutical compositions including the compound, as well as a method of sequestering one or more anti-PEG antibodies present in an individual and a method of inhibiting an immune reaction to a treatment with a PEGylated active agent.
-
公开(公告)号：US20230302043A1
公开(公告)日：2023-09-28
申请号：US18143026
申请日：2023-05-03
IPC分类号： A61K31/765 , C08L67/02 , A61L27/38 , A61K9/00 , A61P29/00 , A61P31/04 , A61K31/047
CPC分类号： A61K31/765 , A61K9/0024 , A61K31/047 , A61L27/3839 , A61P29/00 , A61P31/04 , C08L67/02 , A61K2123/00 , C08L2312/06
摘要： A method of treating infection and/or inflammation in a subject includes steps of providing a polyester biomaterial comprising diol monomers and at least first carboxylate monomers, wherein the first carboxylate monomers are itaconate; and administering the polyester biomaterial to the subject. The polyester biomaterial can be in the form of a biomimetic, and characterized by hydrolytic degradability. The polyester biomaterial may further include second carboxylate monomers. The biomaterial can be poly(itaconate-co-citrate-co-octanediol).
-
7.发明公开公开(公告)号：US20230256003A1
公开(公告)日：2023-08-17
申请号：US18009665
申请日：2021-06-24
发明人： Jong-Ho Kim , Chul-Su Yang , DaBin Yim
摘要： A 2D TMD nanosheet functionalized with an amphiphilic block polymer compound of the present disclosure has scavenging activity for intracellular and mitochondrial ROS and the scavenging activity is maintained well at low pH, and further, inhibits the excessively increased secretion of inflammatory cytokines in microbial infection, exhibits antibacterial activity, and can increase survivability and prevent aggravation of symptoms in an animal model of sepsis, it can be provided as an anti-inflammatory/antioxidant agent for prevention and treatment of sepsis and septic shock.
-
公开(公告)号：US20230131227A1
公开(公告)日：2023-04-27
申请号：US17907953
申请日：2021-03-12
申请人： REDWOOD PHARMA AB
发明人： Martin VIDAEUS , Hans AGELAND , Ulf BJÖRKLUND , Gerhard GARHÖFER
IPC分类号： A61K9/00 , A61K31/765 , A61K47/14 , A61P27/04
摘要： The present invention provides a pharmaceutical composition comprising a reversely thermo-reversible hydrogel as active ingredient, for administration to the eye of mammalian subjects. In particular, it relates to a pharmaceutical composition for use in, and a method for, the ophthalmic treatment of dry eye disease.
-
9.发明授权公开(公告)号：US11612658B2
公开(公告)日：2023-03-28
申请号：US16949237
申请日：2020-10-21
申请人： SANTEN SAS
IPC分类号： A61K9/107 , A61K47/18 , A61K9/00 , A61K31/765 , A61K38/13 , A61K31/14 , A61L12/14 , C07C211/63
摘要： Compositions containing quaternary compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, and the composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Also, ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions.
-
10.发明授权公开(公告)号：US11612584B2
公开(公告)日：2023-03-28
申请号：US16753899
申请日：2018-10-05
申请人： GEDEA BIOTECH AB
发明人： Ulf Ellervik , Olov Sterner , Helena Strevens , Sophie Manner
IPC分类号： A61K31/366 , A61P31/04 , A61K31/191 , A61K31/765 , A61K9/00 , A61K45/06
摘要： The present invention concerns a pharmaceutical composition comprising a compound of Formula I for use in the treatment and/or prevention of microbial infections. Furthermore, the present invention concerns a method for prevention and/or reduction of biofilm formation.
-
-
-
-
-
-
-
-
-
搜索结果
1454 条记录 (耗时 0.029 秒)
